ArticleJournal of the American College of Cardiology2014
Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
Article in Journal of the American College of Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02307422 (Genetic Polymorphisms Associating With CAD, Inflammatory Biomarkers, and Oxidized Phospholipids in a Greek Population), which is not on this map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Polymorphisms Associating With CAD, Inflammatory Biomarkers, and Oxidized Phospholipids in a Greek Population
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis.Current pharmaceutical design · 2022Pooled it
- The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk.European journal of preventive cardiology · 2025Trial
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.Circulation · 2016Trial
- Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.Journal of thrombosis and thrombolysis · 2016Trial
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.Journal of lipid research · 2016Trial
- Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.Journal of the American College of Cardiology · 2015Trial
- Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.JAMA cardiology · 2026Article
- Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.The Journal of clinical investigation · 2026Observational
- Metabolomic Profiles of Inflammation Associated With Incident Ischemic Stroke Risk in Women.Neurology · 2026Article
- Broken adaptive ridge method for variable selection in generalized partly linear models with application to the coronary artery disease data.Journal of Computational Mathematics and Data Science · 2025Article
- Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.Journal of the American College of Cardiology · 2025Article
- Upregulation and diagnostic potential of Interleukin-36 cytokine isoforms in dilated cardiomyopathy: evidence from human and murine models.Molecular biology reports · 2025Article
- Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease.Journal of lipid research · 2025Article
- Features of the monocyte inflammatory response in patients with premature coronary artery disease.Biophysics reports · 2025Article
- The functions of apolipoproteins and lipoproteins in health and disease.Molecular biomedicine · 2024Review
- Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review.Cardiology and therapy · 2024Review
- Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Journal of the American Heart Association · 2024Review
- Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.Current atherosclerosis reports · 2024Review
- Apolipoprotein(a) production and clearance are associated with plasma IL-6 and IL-18 levels, dependent on ethnicity.Atherosclerosis · 2024Article
- Oxidized phospholipids in cardiovascular disease.Nature reviews. Cardiology · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
objectivesThe aim of this study was to assess the influence of pro-inflammatory interleukin (IL)-1 genotype status on the risk for coronary artery disease (CAD), defined as >50% diameter stenosis, and cardiovascular events mediated by oxidized phospholipids (OxPLs) and lipoprotein (Lp) (a).
backgroundOxPLs are pro-inflammatory, circulate on Lp(a), and mediate CAD. Genetic variations in the IL-1 region are associated with increased inflammatory mediators.
methodsIL-1 genotypes, OxPL on apolipoprotein B-100 (OxPL/apoB), and Lp(a) levels were measured in 499 patients undergoing coronary angiography. The composite genotype termed IL-1(+) was defined by 3 single-nucleotide polymorphisms in the IL-1 gene cluster associated with higher levels of pro-inflammatory cytokines. All other IL-1 genotypes were termed IL-1(-).
resultsAmong IL-1(+) patients, the highest quartile of OxPL/apoB was significantly associated with a higher risk for CAD compared with the lowest quartile (odds ratio [OR]: 2.84; p = 0.001). This effect was accentuated in patients age ≤60 years (OR: 7.03; p < 0.001). In IL-1(-) patients, OxPL/apoB levels showed no association with CAD. The interaction was significant for OxPL/apoB (OR: 1.99; p = 0.004) and Lp(a) (OR: 1.96; p < 0.001) in the IL-1(+) group versus the IL-1(-) group in patients age ≤60 years but not in those age >60 years. In IL-1(+) patients age ≤60 years, after adjustment for established risk factors, high-sensitivity C-reactive protein, and Lp(a), OxPL/apoB remained an independent predictor of CAD. IL-1(+) patients above the median OxPL/apoB presented to the cardiac catheterization laboratory a mean of 3.9 years earlier (p = 0.002) and had worse 4-year event-free survival (death, myocardial infarction, stroke, and need for revascularization) compared with other groups (p = 0.006).
conclusionsOur study suggests that IL-1 genotype status can stratify population risk for CAD and cardiovascular events mediated by OxPL. These data suggest a clinically relevant biological link between pro-inflammatory IL-1 genotype, oxidation of phospholipids, Lp(a), and genetic predisposition to CAD and cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.